血管生成素在肝细胞癌中的研究进展

张华敏; 赵正斌; 熊亚星; 陈红

血管生成素在肝细胞癌中的研究进展

兰州大学第一医院感染科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 3892
- HTML全文浏览量: 16
- PDF下载量: 1273
- 被引次数: 0
出版历程
- 出版日期: 2011-04-20

Research progress of angiopoietins in hepatocellular carcinoma

摘要

摘要: 实体瘤的生长和转移离不开丰富的血液供应。肝细胞癌（HCC）是一种极富含血管的实质肿瘤之一,新生血管的形成在HCC中起了很大的作用。近年来发现许多血管生成因子参与血管再生过程,其中血管生成素家族（Angs）在HCC血管新生、肿瘤发展中有重要作用。Angs是一种内皮细胞特异性的促血管生长因子,目前发现Angs共有4种亚型:Ang-1、Ang-2、Ang-3、Ang-4,均能与内皮细胞特异酪氨酸激酶-2受体（Tie-2,又称作Tek）结合。其中Ang-1和Ang-2在新生血管方面的调节中起主要作用,深入了解Angs在HCC血管新生中的作用,将为临床上HCC的诊断和治疗提供重要的理论依据。
- 癌,肝细胞 /
- 血管生成素类
Abstract: The growth and metastasis of solid tumors constantly require blood vascular supply. Hepatocellular carcinoma (HCC) is one of the most vascular solid tumors, in which angiogenesis plays an important role. In recent years, many angiogenic factors have been found involved in the process of angiogenesis. Angiopoietin family (Angs) is one of the them which plays an important role in the growth and progression of HCC. Angiopoietin is a family of growth factors specific for the vascular endothelium that consists of 4 known members: Ang-1, Ang-2, Ang-3 and Ang-4. Angiopoietins were identified as ligands for Tie2 (Tie2; also called Tek) , a member of the endothelial cell type specific receptor tyrosine kinase family. Ang-1 and Ang-2 are considered to play major roles in the regulation of angiogenesis. Therefore, further understanding the role of angiopoietins in HCC may represent an important theoretical basis for diagnosis and treatment for HCC.
- carcinoma /
- hepatocellular

HTML全文

参考文献(30)

[1]Makrilia N, Lappa T, Xyla V, et al.The role of angiogenesis insolid tumours:An overview[J].European Journal of InternalMedicine, 2009, 20 (7) :663-671.

[2]熊维玲, 周春.血管生成素与妊娠[J].国际妇产科学杂志, 2009, 36 (1) :8-14.

[3]何荣荣, 周怀君.血管生成素与肿瘤血管生成[J].江苏医药, 2009, 35 (2) :224-226.

[4]Tanaka S, Mori M, Sakamoto Y, et al.Biologic significanceof angiopoietin-2 expression in human hepatocellularcarcinoma[J].J Clin Invest, 1999, 103 (3) :341-345.

[5]Moon WS, Lee DG, Koh GY, et al.Overexpression of VEGFand angiopoietin 2:a key to high vascularity of hepatocellularcarcinoma?[J].Mod Pathol, 2003, 16 (6) :552-557.

[6]Stoeltzing O, Ahmad SA, Liu WB, et al.Angiopoietin-1inhibits vascular permeability, angiogenesis, and growth ofhepatic colon cancer tumors[J].Cancer Res, 2003, 63 (12) :3370-3377.

[7]Hayes AJ, Huang WQ, Yu J, et al.Expression and functionof angiopoietin-1 in breast cancer[J].Br J Cancer, 2000, 83 (9) :1154-1160.

[8]Takahama M, Tsutsumi M, Tsujiuchi T, et al.Enhancedexpression of Tie2, its ligand angiopoietin-1, vascularendothelial growth factor, and CD31 in human non-small celllung carcinomas[J].Clin Cancer Res, 1999, 5 (9) :2506-2510.

[9]Shim W, The M, Mack P, et al.inhibition of angiopoietin-1expression in tumor cells by an antiserum RNA approachinhibited xenograft tumor growth in immunodeficient mice[J].Int J Cancer, 2001, 94 (1) :6-15.

[10]Kunz P, Hoffend J, Altmann A, et al.Angiopoietin-2overexpression in morris hepatoma results in increasedtumor perfusion and induction of critical angiogenesis-promoting genes[J].J Nucl Med, 2006, 47 (9) :1515-1524.

[11]Etoh T, Inoue H, Tanaka S, et al.Angiopoietin-2 is related totumor angiogenesis in gastric carcinoma:possible in vivoregulation via induction of proteases[J].Cancer Res, 2001, 61 (5) :2145-2153.

[12]Yamaguchi R, Yano H, Lemura A, et al.expression ofvascular endothelial growth factor inhuman hepatocellularcarcinoma[J].Hepatology, 1998, 28 (1) :68-77.

[13]何胜利, 高勇, 刘道勇, 等.Ang-1、Ang-2和Tie-2表达与肝癌血管生成的关系[J].临床肿瘤学杂志, 2009, 14 (5) :439-442.

[14]Mitsuhashi N, Shimizu H, Ohtsuka M, et al.Angiopoietins andTie-2 expression in angiogenesis and proliferation of humanhepatocellular carcinoma[J].Hepatology, 2003, 37 (5) :1105-1113.

[15]Torimura T, Ueno T, Kin M, et al.Overexpression ofangiopoietin-1 and angiopoietin-2 in hepatocellularcarcinoma[J].J Hepatol, 2004, 40 (5) :799-807.

[16]周晔, 冯虹.促血管生成素1、2及Tie 2受体mRNA在卵巢上皮性浆液性腺癌中的表达[J].临床肿瘤学杂志, 2009, 14 (2) :144-146.

[17]Zhang ZL, Liu ZS, Sun Q.Expression of angiopoietins, Tie2and vascular endothelial growth factor in angiogenesisand progression of hepatocellular carcinoma[J].World JGastroenterol, 2006, 12 (26) :4241-4245.

[18]Hata K, Nakayama K, Fujiwaki R, et al.Expression ofthe angopoietin-1, angopoietin-2, Tie2, and vascularendothelial growth factor gene in epithelial ovarian cancer[J].Gynecol Oncol, 2004, 93 (1) :215-222.

[19]Chen ZB, Shen SQ, Ding YM, et al.The angiogenic andprognostic implications of VEGF, Ang-1, Ang-2, andMMP-9 for hepatocellular carcinoma with background ofhepatitis B virus[J].Med Oncol, 2009, 26 (3) :365-371.

[20]Peng L, Sun J, Wang WD, et al.Biological effect of ectopicexpression of angiopoietin-1 and-2 in hepatocellularcarcinoma cell line[J].Hepatobiliary Pancreat Dis Int, 2003, 2 (1) :94-97.

[21]NgIO, Poon RTP, Lee JMF, et al.Microvessel density, vascular endothelial growth factor and its receptors Flt-1and Flk-1/KDR in hepatocellular carcinoma[J].Am J ClinPathol, 2001, 116 (6) :838-845.

[22]Krikun G, Schatz F, Finlay T, et al.Expression ofangiopoietin-2 by human endometrial endothelial cells:regulation by hypoxia and inflammation[J].Biochem BiophysRes Commun, 2000, 275 (1) :159-163.

[23]Koga K, Todaka T, Morioka M, et al.Expression ofangiopoietin-2 in human glioma cells and its role forangiogenesis[J].Cancer Res, 2001, 61 (16) :6248-6254.

[24]Oh H, Takagi H, Suzuma K, et al.Hypoxia and vascularendothelial growth factor selectively up-regulateangiopoietin-2 in bovine microvascular endothelial cells[J].J Biol Chem, 1999, 274 (22) :15732-15739.

[25]Shimada M, Takenaka K, Gion T, et al.Prognosis of recurrenthepatocellular carcinoma:a 10-year surgical experience inJapan[J].Gastroenterology, 1996, 111 (3) :720-726.

[26]Abdulmalek K, Ashur F, Ezer N, et al.Differential expressionof Tie-2 receptors and angiopoietins in response to in vivohypoxia in rats[J].Am J Physiol Lung Cell Mol Physiol, 2001, 281 (3) :L582-590.

[27]Kuboki S, Shimizu H, Mitsuhashi N, et al.Angiopoietin-2levels in the hepatic vein as a useful predictor of tumorinvasiveness and prognosis in human hepatocellularcarcinoma[J].J Gastroenterol Hepatol, 2008, 23 (7 Pt2) :e157-164.

[28]方玲, 顾向明, 沈庆茂, 等.促血管生成素2在常见恶性肿瘤中的早期筛查研究[J].现代检验医学杂志, 2010, 25 (1) :81-83.

[29]张雷雷, 胥全彬, 马清钧.血管生成素的结构与功能的研究进展[J].生物技术通讯, 2006, 17 (2) :248-251.

[30]Kerbel RS.Antiangiogenic therapy:a universal chemos-ensitization strategy for cancer?[J].Science, 2006, 312 (5777) :1171-1175.

施引文献

资源附件(0)

访问统计